170 related articles for article (PubMed ID: 38073220)
1. [Research progress on immunohistochemical diagnostic markers for malignant pleural mesothelioma].
Pu YQ; Zhang YP; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Nov; 41(11):869-875. PubMed ID: 38073220
[TBL] [Abstract][Full Text] [Related]
2. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
3. Pleural neoplastic pathology.
Karpathiou G; Stefanou D; Froudarakis ME
Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
[TBL] [Abstract][Full Text] [Related]
4. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
[TBL] [Abstract][Full Text] [Related]
5. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
6. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
7. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
[TBL] [Abstract][Full Text] [Related]
11. Non-asbestos-related malignant pleural mesothelioma.
Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
[TBL] [Abstract][Full Text] [Related]
12. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
13. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
14. Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma.
Hashimoto M; Sato A; Kuroda A; Nakamura A; Nakamichi T; Kondo N; Yuki M; Nabeshima K; Tsujimura T; Hasegawa S
Gen Thorac Cardiovasc Surg; 2020 Aug; 68(8):820-827. PubMed ID: 31981139
[TBL] [Abstract][Full Text] [Related]
15. Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value.
Shaker N; Wu D; Abid AM
Diagn Cytopathol; 2022 Nov; 50(11):532-537. PubMed ID: 36069384
[TBL] [Abstract][Full Text] [Related]
16. Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea.
Kim YK; Kim JS; Lee KW; Yi CA; Goo JM; Jung SH
Korean J Radiol; 2016; 17(4):545-53. PubMed ID: 27390546
[TBL] [Abstract][Full Text] [Related]
17. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)].
Multidisciplinary Committee of Oncology, Chinese Physicians Association
Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):383-394. PubMed ID: 33902201
[TBL] [Abstract][Full Text] [Related]
18. Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology.
Nakai T; Matsumoto Y; Sasada S; Tanaka M; Tsuchida T; Ohe Y; Motoi N
Jpn J Clin Oncol; 2019 Jun; 49(6):559-566. PubMed ID: 30882147
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
Liu H; Wu L; Ji K; Wang W
Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]